Qihan Biotech Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Hangzhou Zhejiang China

Primary Industry

Biotechnology

About

Established in 2017 and based in Hangzhou, China, Qihan Biotech is a biotechnology company that provides novel immune-privileged cell and organ therapies. The company's chairman, Steven Holtzman is a former CEO of Decibel Therapeutics, former EVP corporate development of Biogen, and founder of DNX. The company's founder & CEO, Luhan Yang holds a PhD in Human Biology and Translational Medicine from Harvard Medical School. She is the co-founder, former president & CSO of eGenesis, and co-inventor of CRISPR-Cas9 technologies. In September 2023, Qihan Biotech raised more than CNY 100 million in pre-series B funding from new investor Jinkong Capital. The company builds an immune-privileged cell and organ platform to produce cells and organs that can evade immune attacks, such as natural killer cells for immune oncology, cardiomyocytes, neurons, and islet cells for regenerative medicine. It also produces animals with enhanced agronomical traits or multi-disease resistance in agriculture through multi-genome editing technology. The company will use the funds to support product iteration and global development of gene-edited stem cell products.

Current Investors

Alta Partners, ARCH Venture Partners, Sequoia Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy

Website

www.qihanbio.com

Verticals

HealthTech

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.